Market Intelligence, Clinical Progress, and High-Purity Reagents for NSCLC, Lymphoma, and Neuroblastoma Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ALK drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ALK ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View ALK Products |
| Resistance Panel | ALK Mutant Recombinant Kinase Domain (G1202R, F1174L, I1171T) Sequence-verified drug-resistant mutants for next-gen inhibitor screening. |
View ALK Products |
| Gene Delivery | ALK Full-Length ORF Lentivirus For stable Ba/F3 or CHO-K1 cell line construction. CMV promoter, Puromycin selection. |
View ALK Products |
| Benchmark Ab | Anti-ALK (Reference Clone) Recombinant monoclonal for flow cytometry and binding assay positive control. |
View ALK Products |
| Validator | ALK siRNA Set (3 unique targets) For specific knockdown validation in functional assays, reducing false positives. |
View ALK Products |
| Fusion Partner | EML4 Recombinant Protein EML4-ALK fusion screening and interaction assays. |
View EML4 Products |
| Selectivity Panel | ROS1 Recombinant Kinase Domain Critical off-target liability testing; ALK vs ROS1 selectivity assays. |
View ROS1 Products |
| Selectivity Panel (Additional) | LTK Recombinant Protein Leukocyte tyrosine kinase, the closest ALK homolog for subfamily counter-screening. |
View LTK Products |
| Pathway Companion | MET (c-Met) Recombinant Protein Bypass resistance mechanism validation; Crizotinib cross-reactivity testing. |
View MET Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Resistance Mutant Screening (G1202R, F1174L, I1171T) | Purified mutant kinase domains with verified ATP-binding site integrity; Sequence-confirmed via mass spec |
| CNS Penetration Evaluation (Human/Mouse/Cyno) | Ortholog protein panel (Human/Mouse/Cynomolgus ALK ECD) with >95% purity for cross-species binding kinetics |
| Selectivity vs ROS1/MET Kinome | Homologous kinase panel (ROS1, MET, InsR) for counter-screening; Endotoxin-controlled for sensitive cellular assays |
| Subfamily Off-target Toxicity (LTK) | Purified LTK kinase domain for ALK subfamily selectivity profiling; mass spec verified |
| Internalization Efficiency (ADC/CAR-T Development) | Full-length ALK lentivirus for stable cell line generation preserving native conformation and glycosylation patterns |
| Fusion Protein Detection (EML4-ALK) | Dual-target assay components enabling bivalent detection specificity |
| False Positives in Cell Assays | Validated siRNA included for specificity checks and genetic knockdown baselines |
Live ALK R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ALK therapeutics is intensifying, with major players shifting focus from first-generation TKIs to next-generation brain-penetrant inhibitors, fourth-generation macrocycles, PROTACs, and ALK-targeted ADCs. As lorlatinib resistance mutations (particularly G1202R compound mutations) become prevalent, the next wave of R&D targets allosteric inhibitors and proteolysis-targeting chimeras (PROTACs) to overcome kinase domain steric hindrance. Simultaneously, the low expression of ALK in normal adult tissues provides an attractive safety window for biologics targeting the extracellular domain (CD246), driving ADC, CAR-T, and bispecific antibody development in pediatric neuroblastoma and ALCL.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Next-Gen TKI (3rd/4th Gen) | Pfizer, Roche, Takeda, Nuvalent | NSCLC (CNS metastases), Relapsed ALCL | Mutant Kinase Activity Panel (G1202R, F1174C, I1171N) with ATP-competitive binding validation |
| ADC / CAR-T | Takeda, Daiichi Sankyo, Various Biotechs | ALK+ solid tumors, Neuroblastoma, ALCL | Internalization Assay (Need high-purity ECD-Fc for binding affinity; Full-length lentivirus for conformational epitope preservation) |
| Bispecific (ALK x CD3) | Takeda, Xencor | Relapsed ALCL, Neuroblastoma | Cell Surface Density Calibration (Need lentivirus-transduced stable lines with defined receptor expression) |
| PROTAC Degraders | Arvinas, Cullgen, C4 Therapeutics | Resistant NSCLC | Binary Interaction Assay (Ternary complex formation; Need purified ligase + ALK mutants) |